Preclinical studies indicate that eADO inhibits anti-tumor T cell activity by binding to A2AR, while simultaneously enhancing the immunosuppressive functions of tumor-associated fibroblasts and myeloid cells through its interaction with A2BR [48, 49]. This evidence concerns the gene ADORA2A and neoplasm.